The Role of miRNAs in COVID-19 Disease

Fani, Mona; Zandi, Milad; Ebrahimi, Saeedeh; Soltani, Saber; Abbasi, Samaneh

doi:10.2217/fvl-2020-0389

Cited by 63 publications

(76 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, antagonist miR (antimiR) and miR mimic could be innovative approach for the treatment of COVID‐19 infections (Rizkita & Astuti, 2021 ). However, miRNA‐COVID‐19 interaction is a complex process that may enhance or suppress viral replication (El‐Nabi et al, 2020 ; Fani et al, 2021 ).…”

Section: Future Strategy Using Mirnas Against Covid‐19mentioning

confidence: 99%

miRNAs; a novel strategy for the treatment of COVID‐19

Hao

Ebrahimi

Keivan

et al. 2021

Cell Biology International

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID‐19) is the seventh member of the bat severe acute respiratory syndrome family. COVID‐19 can fuse their envelopes with the host cell membranes and deliver their genetic material. COVID‐19 attacks the respiratory system and stimulates the host inflammatory responses, enhances the recruitment of immune cells, and promotes angiotensin‐converting enzyme 2 activities. Patients with confirmed COVID‐19 may have experienced fever, dry cough, headache, dyspnea, acute kidney injury, acute respiratory distress syndrome, and acute heart injury. Several strategies such as oxygen therapy, ventilation, antibiotic or antiviral therapy, and renal replacement therapy are commonly used to decrease COVID‐19‐associated mortality. However, these approaches may not be good treatment options. Therefore, the search for an alternative‐novel therapy is urgently important to prevent the disease progression. Recently, microRNAs (miRNAs) have emerged as a promising strategy for COVID‐19. The design of oligonucleotide against the genetic material of COVID‐19 might suppress virus RNA translation. Several previous studies have shown that host miRNAs play an antiviral role and improve the treatment of patients with COVID‐19. miRNAs by binding to the 3′‐untranslated region (UTR) or 5′‐UTR of viral RNA play an important role in COVID‐19‐host interplay and viral replication. miRNAs interact with multiple pathways and reduce inflammatory biomarkers, thrombi formation, and tissue damage to accelerate the patient outcome. The information in this review provides a summary of the current clinical application of miRNAs for the treatments of patients with COVID‐19.

show abstract

Section: Future Strategy Using Mirnas Against Covid‐19mentioning

confidence: 99%

miRNAs; a novel strategy for the treatment of COVID‐19

Hao

Ebrahimi

Keivan

et al. 2021

Cell Biology International

View full text Add to dashboard Cite

show abstract

“…microRNAs can inhibit SARS-CoV-2 infection by targeting its protein-expressing genes related to structural and nonstructural proteins. microRNAs can inhibit viral DNA implication, suppression of cellular receptors, and inhibition of associated viral proteins [ 94 ]. However, less information is available about how microRNAs regulate SARS-CoV-2 gene expression in the host kidney cells to regulate viral DNA amplifications.…”

Section: Micrornas In Covid-19 Diseasementioning

confidence: 99%

Coronavirus Disease (COVID)-19 and Diabetic Kidney Disease

Srivastava

Chand

et al. 2021

Pharmaceuticals

View full text Add to dashboard Cite

The present review describes COVID-19 severity in diabetes and diabetic kidney disease. We discuss the crucial effect of COVID-19-associated cytokine storm and linked injuries and associated severe mesenchymal activation in tubular epithelial cells, endothelial cells, and macrophages that influence neighboring cell homeostasis, resulting in severe proteinuria and organ fibrosis in diabetes. Altered microRNA expression disrupts cellular homeostasis and the renin-angiotensin-system, targets reno-protective signaling proteins, such as angiotensin-converting enzyme 2 (ACE2) and MAS1 receptor (MAS), and facilitates viral entry and replication in kidney cells. COVID-19-associated endotheliopathy that interacts with other cell types, such as neutrophils, platelets, and macrophages, is one factor that accelerates prethrombotic reactions and thrombus formation, resulting in organ failures in diabetes. Apart from targeting vital signaling through ACE2 and MAS, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections are also associated with higher profibrotic dipeptidyl transferase-4 (DPP-4)-mediated mechanisms and suppression of AMP-activated protein kinase (AMPK) activation in kidney cells. Lowered DPP-4 levels and restoration of AMPK levels are organ-protective, suggesting a pathogenic role of DPP-4 and a protective role of AMPK in diabetic COVID-19 patients. In addition to standard care provided to COVID-19 patients, we urgently need novel drug therapies that support the stability and function of both organs and cell types in diabetes.

show abstract

“…Therefore, the potential diagnostics use of miRNAs with other respiratory viruses, such as the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is completely reasonable. Two recently works have reviewed the literature on the potential role of cellular miRNAs in the SARS-CoV-2-host interplay as a therapeutic option in coronavirus disease 2019 (COVID-19) patients (Fani et al, 2021;Zhang et al, 2021). The main conclusions of these two works are that miRNAs can inhibit the SARS-CoV-2 infection by interfering in various biological processes; blocking the angiotensin-converting enzyme 2 (ACE2) or the transmembrane protease serine 2 (TMPRSS2) as well as regulate the cytokine storm.…”

Section: Mirnas and Diseasesmentioning

confidence: 99%